HSG

HSG, formerly known as Sequoia Capital China, is a prominent venture capital and private equity firm with a global focus on technology, healthcare, and consumer sectors. Established in 2005, HSG operates offices in key international cities including Hong Kong, Shanghai, Beijing, Shenzhen, London, Tokyo, and Singapore, managing over $55 billion in assets for leading institutional investors. The firm has supported over 1,500 companies, fostering innovation and entrepreneurship through investments in transformative technologies and high-growth business models. HSG has a track record of success, with more than 160 portfolio companies having gone public and over 140 achieving unicorn status. It has developed a comprehensive investment platform that encompasses seed, venture, growth, buyout, and infrastructure investing, as well as public equities. HSG is dedicated to empowering entrepreneurs and companies to create enduring enterprises while delivering strong returns to its limited partners. Through its extensive resources and industry expertise, HSG provides significant advantages to the companies it partners with.

Wang Chenyu

Vice President

Sakshi Chopra

Managing Director

Amit Jain

Managing Director

Cherry Lu

Partner

Ishaan Mittal

Managing Director

Enita Pu

Partner

Harshjit Sethi

Managing Director

Tejeshwi Sharma

Managing Director

Pavel Vyhnalek

Operating Partner

Fu Xin

Partner

Past deals in Health Diagnostics

Cloudphysician

Series A in 2024
Cloudphysician is a prominent provider of Smart-ICU services, utilizing a cloud-based platform to enhance critical care delivery. The company employs advanced technologies such as artificial intelligence, the Internet of Things, and predictive analytics to facilitate real-time clinical decision-making. This innovative approach supports early-stage diagnosis of critical diseases in adults and monitors immunization schedules and growth profiles of newborns, aimed at reducing neonatal mortality rates. By combining medical expertise with technology, Cloudphysician improves patient outcomes and offers hospitals and healthcare providers enhanced monitoring, support, and training, ultimately transforming the landscape of critical care in the healthcare industry.

Taiyi Guanjia

Seed Round in 2024
Taiyi Guanjia is a company that combines technology and medical health innovation, aiming to enhance the insurance industry and create a robust medical and health ecosystem.

Twin Health

Series D in 2023
Twin Health, Inc. is a precision health company focused on reversing diabetes and chronic diseases through its innovative health platform. Founded in 2018 and based in Mountain View, California, with additional offices in India, Twin Health utilizes artificial intelligence and Internet-of-Things technologies to accurately measure and address metabolic health issues, which are often the underlying causes of chronic conditions. The platform incorporates sensors and advanced machine learning to analyze biosignals from wearables, predict metabolic outcomes, and provide personalized treatment recommendations tailored to each patient's metabolic profile. The company has secured significant funding from prominent venture capital firms and holds multiple patents related to its technology, positioning it as a leader in the field of metabolic health.

Su Hui therapy

Seed Round in 2023
HealiRNA develops infectious disease vaccines, tumor vaccines, cell therapy, and protein replacement. They provide mRNA drug research and development, production, clinical trial design, and data analysis services.

hoop

Grant in 2023
hoop is India’s first wellness brand for an active lifestyle! hoop’s wellness range is the answer India needs – effective pain, sleep, stress, workout products crafted with natural ingredients that feel amazing to use.

Spectrum Medical

Series A in 2022
Spectrum Medical is a clinical mass spectrometry product platform that promotes clinical mass spectrometry detection technology to the general public. It has an experienced research and development, operations, and sales team, a standardized GMP production workshop, extensive experience in laboratory construction, and a mature laboratory management system. It provides with complete supporting kits in addition to mastering the core mass spectrometry hardware manufacturing technology and equipment integration development capabilities (maternal and child genetics, nutritional levels, therapeutic drug testing, metabolic monitoring, etc.).

NuProbe

Series B in 2022
NuProbe, Inc. is a genomics and molecular diagnostics company that focuses on noninvasive nucleic acid profiling and diagnostics. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in Shanghai, China, NuProbe has developed a platform that utilizes genetic toehold probes for quantitative PCR mutation detection. The company's innovative technology offers a Sample-In Answer-Out (SIAO) solution, which seamlessly integrates cell-free DNA extraction, qPCR analysis, sequencing, and bioinformatic interpretation. This precision diagnostic technology is designed to facilitate the early detection of cancer and infectious diseases by accurately capturing disease signatures with high sensitivity and multiplexing capability, allowing healthcare professionals to initiate timely interventions for patients.

Qianglian Zhichuang

Series C in 2022
the first high-tech company in China to focus on the treatment of cerebrovascular disease, it has more than four years of product research and development, leading China's cerebrovascular disease intelligence in an all-around way. vertical field of diagnosis and treatment. It has become a well-known brain stroke intelligence diagnosis and treatment platform in China.

Virtue Diagnostics

Series B in 2022
Virtue Diagnostics is an innovative IVD company focused on infectious disease, cancer, and chronic diseases.

Lemonilo

Series C in 2021
PT Lemonilo Indonesia Sehat is an online platform based in Jakarta Barat, Indonesia, that specializes in retailing a diverse range of healthy lifestyle products. Founded in 2016, the company offers food items such as snacks, vegetables, fruits, meat, seafood, baby food, and juices, alongside beauty and personal care products like face and body treatments, dental care items, and essential oils. Lemonilo emphasizes providing natural and affordable options free from over 100 harmful synthetic ingredients, partnering with small and medium enterprises across Indonesia. The company's mission is to promote healthier living among Indonesians by making nutritious and organic products accessible and affordable, thereby enhancing their overall well-being and productivity. In addition to its online presence, Lemonilo also operates retail stores to reach a wider audience.

ABclonal

Series D in 2021
ABclonal Inc. is a life science research and diagnostic reagents provider based in Woburn, Massachusetts, established in 2016. The company specializes in offering a range of biological research agents and services, including next generation sequencing library preparation kits, molecular biology products, catalog antibodies, catalog proteins, ELISA kits, and tools for western blotting. Additionally, ABclonal provides peptide, antibody, and protein services. The company distributes its products through a network that spans Europe, Asia, North America, and Oceania. With a team of scientists from leading universities, ABclonal is committed to enhancing the quality of life science research through its high-quality offerings.

SyMap Medical

Series E in 2021
SyMap Medical focuses on developing and manufacturing a proprietary catheter-based system for renal mapping and ablation, specifically aimed at treating hypertension and various other serious conditions, including heart failure, arrhythmia, and renal failure. The company's core technology platform is based on radiofrequency (RF) ablation, which is integral to its approach in renal nerve mapping and selective ablation. This innovative medical device is designed to enhance treatment options for patients suffering from these significant health issues.

Genki Forest

Venture Round in 2021
Genki Forest is a beverage company specializing in sugar-free and low-calorie drinks, catering to health-conscious consumers seeking flavorful options. The company manufactures a range of products, including sugar-free tea and flavored seltzer water, produced from natural ingredients. By focusing on health and affordability, Genki Forest aims to provide accessible beverage choices that meet the demands of a growing market interested in healthier lifestyles.

Lemonilo

Series B in 2021
PT Lemonilo Indonesia Sehat is an online platform based in Jakarta Barat, Indonesia, that specializes in retailing a diverse range of healthy lifestyle products. Founded in 2016, the company offers food items such as snacks, vegetables, fruits, meat, seafood, baby food, and juices, alongside beauty and personal care products like face and body treatments, dental care items, and essential oils. Lemonilo emphasizes providing natural and affordable options free from over 100 harmful synthetic ingredients, partnering with small and medium enterprises across Indonesia. The company's mission is to promote healthier living among Indonesians by making nutritious and organic products accessible and affordable, thereby enhancing their overall well-being and productivity. In addition to its online presence, Lemonilo also operates retail stores to reach a wider audience.

Genki Forest

Venture Round in 2021
Genki Forest is a beverage company specializing in sugar-free and low-calorie drinks, catering to health-conscious consumers seeking flavorful options. The company manufactures a range of products, including sugar-free tea and flavored seltzer water, produced from natural ingredients. By focusing on health and affordability, Genki Forest aims to provide accessible beverage choices that meet the demands of a growing market interested in healthier lifestyles.

Jianhai Technology

Series B in 2021
Jianhai Technology is an AI whole-course management platform that provides users with post-hospital & post-diagnosis management services.

Neuracle

Series B in 2021
Neuracle is a prominent enterprise in China's neuroscience sector, specializing in neural monitoring and diagnostic technology. Leveraging advanced brain-machine interface technology developed in collaboration with Tsinghua University, Neuracle focuses on innovative research across neuroscience, psychology, and neuroengineering. The company provides comprehensive solutions for the diagnosis, treatment, and rehabilitation of clinical neurological diseases. Its product offerings include digital electroencephalographs that allow healthcare institutions to monitor patients' brain bioelectricity levels and facilitate accurate diagnoses of neural conditions. Neuracle's contributions span various fields, including clinical medicine and management marketing, and the company's research and development efforts have garnered recognition from experts in neuroscience and clinical medicine both domestically and internationally.

ABclonal

Series C in 2021
ABclonal Inc. is a life science research and diagnostic reagents provider based in Woburn, Massachusetts, established in 2016. The company specializes in offering a range of biological research agents and services, including next generation sequencing library preparation kits, molecular biology products, catalog antibodies, catalog proteins, ELISA kits, and tools for western blotting. Additionally, ABclonal provides peptide, antibody, and protein services. The company distributes its products through a network that spans Europe, Asia, North America, and Oceania. With a team of scientists from leading universities, ABclonal is committed to enhancing the quality of life science research through its high-quality offerings.

Jifan Biotechnology

Series A in 2021
Jifan Biotechnology is a biotechnology firm that provides molecular biology reagents, diagnostic raw materials, and kits for research.

NuProbe

Series B in 2021
NuProbe, Inc. is a genomics and molecular diagnostics company that focuses on noninvasive nucleic acid profiling and diagnostics. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in Shanghai, China, NuProbe has developed a platform that utilizes genetic toehold probes for quantitative PCR mutation detection. The company's innovative technology offers a Sample-In Answer-Out (SIAO) solution, which seamlessly integrates cell-free DNA extraction, qPCR analysis, sequencing, and bioinformatic interpretation. This precision diagnostic technology is designed to facilitate the early detection of cancer and infectious diseases by accurately capturing disease signatures with high sensitivity and multiplexing capability, allowing healthcare professionals to initiate timely interventions for patients.

Virta Health

Series D in 2020
Virta Health Corp. is an online specialty medical clinic dedicated to reversing type 2 diabetes without the use of medications or surgery. Founded in 2014 and based in San Francisco, California, the company utilizes a combination of nutritional biochemistry, clinical expertise, data science, and digital solutions to deliver its innovative treatment. Through its continuous remote care platform, Virta provides extensive medical and behavioral support, which has shown significant results in clinical trials; 60% of enrolled patients achieved diabetes reversal after one year, while 94% of insulin users reduced or eliminated their insulin intake. The benefits of Virta's approach extend beyond diabetes, leading to improvements in blood pressure, inflammation, liver function, and body mass index (BMI), thereby transforming the lives of individuals affected by type 2 diabetes.

Miaoshou Doctor

Series D in 2020
Miaoshou Doctor is a healthcare service platform for building an online communication service platform between patients and doctors. It helps healthcare professionals and patients to manage post-diagnosis outcomes and allows doctors to actively follow up with their patient's health through additional counseling and prescriptions. Tao He and Daoliang Han founded the company in 2015 and is based in Beijing, Beijing.

Sibionics

Series B in 2020
SiBionics is a medtech company based in Shenzhen, China, focused on the research and development of active implantable medical devices and medical artificial intelligence. The company specializes in creating innovative solutions for various health conditions, including retinitis pigmentosa, diabetes, cardiovascular diseases, and gastrointestinal tumors. SiBionics develops artificial intelligence technologies for medical imaging and implantable devices, including retinal electrical stimulators and continuous glucose monitors. Their work also encompasses health management, disease screening, and diagnostics, using approaches such as visual coding, medical imaging AI, and big data analytics to enhance patient care and address chronic diseases. Through these advancements, SiBionics aims to provide cost-effective products that improve long-term monitoring and treatment options in the medical field.

Qure AI

Venture Round in 2020
Qure AI is a healthtech startup that uses artificial intelligence assistance for medical imaging diagnostics. The company's mission is to make healthcare affordable and accessible using the power of artificial intelligence. They build deep learning solutions that aid physicians with routine diagnosis and treatment, allowing them to spend more time with patients. Qure AI was founded in 2016 and is based in Mumbai, Maharashtra.

DentaLink China

Series C in 2020
Developer of dental imaging technology and dental clinic management software. The company's software helps dental professionals accurately diagnose patient conditions through oral CT scanning, as well as keep track of patient records and appointments, enabling dental professionals to provide treatment more efficiently.

BGI

Post in 2020
BGI is a biotechnology company specializing in genomics, providing genome sequencing and genetic testing services to research institutions and healthcare professionals. Operating through its subsidiary, Shenzhen Huada Gene Technology Co. Ltd., BGI offers a wide range of services including bioinformatics testing, agricultural genomics research, and proteomics research. The company collaborates with various organizations to enhance research efforts in the pharmaceutical and healthcare sectors. BGI also supplies products such as DNA extraction kits and other related tools, positioning itself as a key player in advancing genetic and genomic research.

Yaoyanshe

Series C in 2019
Yaoyanshe is a Shanghai-based company established in 2012 that operates a technology platform focused on the pharmaceutical research and development industry. It develops an application that facilitates value sharing and trading, providing patients with up-to-date information on treatments and drugs. The platform also supports industry professionals by offering services such as clinical monitoring, project management, biostatistics, and pharmacovigilance. Additionally, it includes features for credit assessments and research project competition analysis, aiming to address critical challenges in the sector and enhance the effectiveness of pharmaceutical R&D. Through its comprehensive database, Yaoyanshe enables medical professionals and patients to access vital healthcare information efficiently.

Tencent Trusted Doctors

Series C in 2019
Tencent Trusted Doctors, a company established in early August 2018 upon the merger of Tencent Doctorwork and Trusted Doctors, is acquiring the start-up in an attempt to create a private healthcare network that provides both online and offline services through the so-called "celebrity effect".

Burning Rock

Series C in 2019
Burning Rock is a cancer diagnostics company that specializes in individualized cancer treatment guidance. Established in March 2014 and headquartered in Beijing, the company utilizes advanced technologies such as Next-Generation Sequencing (NGS) and biomedical informatics to provide tailored solutions for cancer patients. Burning Rock operates a central laboratory in Guangzhou, along with a research and development center in Shanghai, collectively spanning over 10,000 square meters. The company offers a range of services, including tumor molecular pathology detection and cancer therapy selection, addressing the needs of both large hospitals through an in-hospital model and smaller hospitals via a central laboratory model. Its diverse product portfolio includes offerings like Pan-HEME and OncoScreen-WES, primarily generating revenue from its central laboratory business while also engaging in pharmaceutical research and development services.

VoxelCloud

Series B in 2018
VoxelCloud Inc. is a company specializing in cloud computing and artificial intelligence solutions aimed at enhancing the interpretation of medical images and clinical data for healthcare professionals. Founded in 2015 and headquartered in Los Angeles, California, VoxelCloud provides automated medical image analysis and diagnostics services utilizing proprietary algorithms and deep learning techniques. The company focuses on critical clinical areas, including lung cancer, diabetic retinopathy, coronary heart disease, and liver disease, ensuring that medical practitioners receive accurate and timely insights. In addition to its Los Angeles base, VoxelCloud has offices in Shanghai and Suzhou, China, and maintains a research and development team in Phoenix, further expanding its capabilities in the healthcare sector.

Medlinker

Series D in 2018
Medical Alliance is a post of physician social service platform. Users are certified doctors working in the Medical Alliance, they can share knowledge, experience and insights with the other industry elite, to continue to provide high quality content for each other. Application provides a medical quiz, map that case, the anonymous social circles and doctors and other functions, is committed to helping physicians groups, more convenient access to high-quality information from the industry

NuProbe

Series A in 2018
NuProbe, Inc. is a genomics and molecular diagnostics company that focuses on noninvasive nucleic acid profiling and diagnostics. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in Shanghai, China, NuProbe has developed a platform that utilizes genetic toehold probes for quantitative PCR mutation detection. The company's innovative technology offers a Sample-In Answer-Out (SIAO) solution, which seamlessly integrates cell-free DNA extraction, qPCR analysis, sequencing, and bioinformatic interpretation. This precision diagnostic technology is designed to facilitate the early detection of cancer and infectious diseases by accurately capturing disease signatures with high sensitivity and multiplexing capability, allowing healthcare professionals to initiate timely interventions for patients.

Miaoshou Doctor

Series C in 2018
Miaoshou Doctor is a healthcare service platform for building an online communication service platform between patients and doctors. It helps healthcare professionals and patients to manage post-diagnosis outcomes and allows doctors to actively follow up with their patient's health through additional counseling and prescriptions. Tao He and Daoliang Han founded the company in 2015 and is based in Beijing, Beijing.

Medlinker

Series C in 2017
Medical Alliance is a post of physician social service platform. Users are certified doctors working in the Medical Alliance, they can share knowledge, experience and insights with the other industry elite, to continue to provide high quality content for each other. Application provides a medical quiz, map that case, the anonymous social circles and doctors and other functions, is committed to helping physicians groups, more convenient access to high-quality information from the industry

MedGenome

Series C in 2017
MedGenome is a company focused on developing genomics-based diagnostics and research platforms to enhance global health. Its innovative platform leverages advanced genomics technologies, bioinformatics, and big data analytics to analyze the genetic diversity of large populations. This approach aims to uncover the genetic foundations of various health conditions, including cancer, metabolic disorders, eye diseases, and rare diseases. MedGenome provides high-quality genetic diagnostic tests across multiple disease categories, such as immuno-oncology, infectious diseases, and reproductive health. By offering these insights, the company supports patients, pharmaceutical firms, and research institutions in understanding diseases at their genetic and molecular levels, ultimately contributing to improved healthcare outcomes.

Hong Kong Asia Heart Centre

Venture Round in 2017
Hong Kong Asia Heart Centre is a cardiovascular specialist chain that provides various cardiovascular assessment and surgical services. Founded in 1999, The Hong Kong Asian Heart Center has a professional medical team with many years of experience in the treatment of heart disease.

Suburban Diagnostics

Venture Round in 2017
Suburban Diagnostics operates diagnostic centers in Maharashtra, offering a comprehensive range of services in pathology, radiology, and cardiology. The company focuses on delivering accurate diagnoses and precise reporting to enhance patient care. In addition to its diagnostic services, Suburban Diagnostics provides health check-ups, ensuring a holistic approach to health management for its clients. Through its commitment to quality and precision, the company aims to support healthcare providers in improving patient outcomes.

Burning Rock

Series B in 2016
Burning Rock is a cancer diagnostics company that specializes in individualized cancer treatment guidance. Established in March 2014 and headquartered in Beijing, the company utilizes advanced technologies such as Next-Generation Sequencing (NGS) and biomedical informatics to provide tailored solutions for cancer patients. Burning Rock operates a central laboratory in Guangzhou, along with a research and development center in Shanghai, collectively spanning over 10,000 square meters. The company offers a range of services, including tumor molecular pathology detection and cancer therapy selection, addressing the needs of both large hospitals through an in-hospital model and smaller hospitals via a central laboratory model. Its diverse product portfolio includes offerings like Pan-HEME and OncoScreen-WES, primarily generating revenue from its central laboratory business while also engaging in pharmaceutical research and development services.

Farcast

Series B in 2016
Farcast Biosciences is a clinical diagnostic company focused on improving cancer treatment through personalized medicine. Founded in 2019 and based in Madison, Wisconsin, with a laboratory in Bangalore, India, Farcast has developed a human tumor microenvironment platform. This platform allows oncologists and drug developers to evaluate individual tumors by culturing fresh, unmodified tumor fragments, preserving their natural state. By generating detailed response data, Farcast's technology aids in identifying optimal treatment options for patients before they begin therapy. This approach not only enhances the understanding of tumor behavior but also supports researchers in drug development by providing insights into treatment responses using real human tumors and blood samples.

Dongri Zhongyi Guan

Angel Round in 2015
Dongri Zhongyi Guan is a chain organisation for TCM diagnosis and treatment that integrates Internet technologies with the fundamental principles of traditional TCM. Pediatric illnesses, andrological illnesses such as impotence, early ejaculation, prostate, etc., spleen and stomach illnesses, colds and flu, neck and lumbar illnesses, liver and gallbladder illnesses, and other illnesses are all treated by them.

Burning Rock

Series A in 2015
Burning Rock is a cancer diagnostics company that specializes in individualized cancer treatment guidance. Established in March 2014 and headquartered in Beijing, the company utilizes advanced technologies such as Next-Generation Sequencing (NGS) and biomedical informatics to provide tailored solutions for cancer patients. Burning Rock operates a central laboratory in Guangzhou, along with a research and development center in Shanghai, collectively spanning over 10,000 square meters. The company offers a range of services, including tumor molecular pathology detection and cancer therapy selection, addressing the needs of both large hospitals through an in-hospital model and smaller hospitals via a central laboratory model. Its diverse product portfolio includes offerings like Pan-HEME and OncoScreen-WES, primarily generating revenue from its central laboratory business while also engaging in pharmaceutical research and development services.

MedGenome

Series B in 2015
MedGenome is a company focused on developing genomics-based diagnostics and research platforms to enhance global health. Its innovative platform leverages advanced genomics technologies, bioinformatics, and big data analytics to analyze the genetic diversity of large populations. This approach aims to uncover the genetic foundations of various health conditions, including cancer, metabolic disorders, eye diseases, and rare diseases. MedGenome provides high-quality genetic diagnostic tests across multiple disease categories, such as immuno-oncology, infectious diseases, and reproductive health. By offering these insights, the company supports patients, pharmaceutical firms, and research institutions in understanding diseases at their genetic and molecular levels, ultimately contributing to improved healthcare outcomes.

Tencent Trusted Doctors

Series B in 2015
Tencent Trusted Doctors, a company established in early August 2018 upon the merger of Tencent Doctorwork and Trusted Doctors, is acquiring the start-up in an attempt to create a private healthcare network that provides both online and offline services through the so-called "celebrity effect".

KFit

Seed Round in 2015
KFit gets you into the best fitness studios, classes and gyms in your city. Get access to unlimited group fitness classes and activities with just one monthly membership. Transform your workouts.Never get bored. Discover new ways to move. Take as many classes per month as you’d like. Try a different studio everyday. It’s time to work out the way you want to.

EndoChoice

Series D in 2015
EndoChoice is a medical technology company specializing in the design and commercialization of products and services for gastrointestinal (GI) care. Headquartered in Alpharetta, Georgia, EndoChoice offers a comprehensive range of products, including single-use devices, infection control solutions, diagnostics, and advanced imaging systems. The company's proprietary product portfolio features the Full Spectrum Endoscopy™ System, known as Fuse™, which includes colonoscopes and gastroscopes equipped with multiple imagers. This innovative system enables physicians to achieve a 330-degree field of view, significantly improving the detection of polyps compared to traditional endoscopes. With a direct sales organization serving over 2,000 customers in the United States and partnerships with 34 distributors globally, EndoChoice has established a strong presence in the market. Founded in 2008, the company experienced rapid growth and was recognized by Inc. Magazine as one of the fastest-growing companies in the U.S. before its acquisition by Boston Scientific in 2016.

Medlinker

Series A in 2015
Medical Alliance is a post of physician social service platform. Users are certified doctors working in the Medical Alliance, they can share knowledge, experience and insights with the other industry elite, to continue to provide high quality content for each other. Application provides a medical quiz, map that case, the anonymous social circles and doctors and other functions, is committed to helping physicians groups, more convenient access to high-quality information from the industry

Tencent Trusted Doctors

Series A in 2014
Tencent Trusted Doctors, a company established in early August 2018 upon the merger of Tencent Doctorwork and Trusted Doctors, is acquiring the start-up in an attempt to create a private healthcare network that provides both online and offline services through the so-called "celebrity effect".

Cloudnine Hospitals

Series B in 2013
Cloudnine Hospitals, founded in 2007 by Dr. R. Kishore Kumar and his co-founders, is a leading healthcare provider in India specializing in maternal, gynecological, neonatal, and pediatric care. With a mission to elevate healthcare standards, Cloudnine aims to transform societal attitudes towards pregnancy, promoting the idea that it is a celebration of life rather than an illness. The organization offers a wide range of services, including support for infertility, conception, and delivery, while ensuring comprehensive medical care throughout pregnancy and beyond. Cloudnine operates over 20 facilities across major cities such as Bengaluru, Chennai, Gurgaon, Mumbai, Pune, and Chandigarh, with plans for further expansion to enhance access to quality healthcare for women and children throughout India. The hospital group is committed to maintaining international standards of care, reflecting its vision of providing world-class healthcare services.

ASG Eye Hospital

Venture Round in 2013
ASG Eye Hospitals is a chain of super-specialty eye hospitals operating in various cities across India, including regions in North and North East India, as well as states like Rajasthan, Uttar Pradesh, and Madhya Pradesh. Founded by ophthalmology experts from AIIMS, New Delhi, the hospital network focuses on delivering comprehensive diagnosis, treatment, and surgical services for a wide array of ocular conditions. ASG Eye Hospitals specializes in treatments for cataracts, diabetic retinopathy, glaucoma, macular degeneration, and eye tumors, utilizing advanced technology to enhance patient care. The organization employs highly skilled and trained professionals, ensuring that patients receive world-class surgical expertise and care tailored to their vision needs.

EndoChoice

Venture Round in 2013
EndoChoice is a medical technology company specializing in the design and commercialization of products and services for gastrointestinal (GI) care. Headquartered in Alpharetta, Georgia, EndoChoice offers a comprehensive range of products, including single-use devices, infection control solutions, diagnostics, and advanced imaging systems. The company's proprietary product portfolio features the Full Spectrum Endoscopy™ System, known as Fuse™, which includes colonoscopes and gastroscopes equipped with multiple imagers. This innovative system enables physicians to achieve a 330-degree field of view, significantly improving the detection of polyps compared to traditional endoscopes. With a direct sales organization serving over 2,000 customers in the United States and partnerships with 34 distributors globally, EndoChoice has established a strong presence in the market. Founded in 2008, the company experienced rapid growth and was recognized by Inc. Magazine as one of the fastest-growing companies in the U.S. before its acquisition by Boston Scientific in 2016.

Betta Pharmaceuticals

Series B in 2013
Betta Pharmaceuticals Co., Ltd. is a prominent Chinese pharmaceutical company, established in 2003 and headquartered in Hangzhou. It specializes in the research, development, manufacturing, and marketing of innovative medicines aimed at treating malignant tumors, diabetes, and cardio-cerebrovascular diseases. Among its notable products is Icotinib hydrochloride, a reversible tyrosine kinase inhibitor used for non-small-cell lung cancer, which has garnered recognition for being the first targeted anti-cancer drug developed in China. Betta is actively engaged in over 20 new drug development projects and has formed strategic partnerships, including an agreement with Amgen Inc. for marketing Vectibix in China. The company prides itself on its independent intellectual property rights and has received numerous awards for its contributions to pharmaceutical innovation, including multiple national science and technology prizes. With a workforce nearing 1,000 employees, including a team of highly educated professionals, Betta Pharmaceuticals is dedicated to enhancing public health through the development of high-quality, affordable medications.

Suburban Diagnostics

Venture Round in 2012
Suburban Diagnostics operates diagnostic centers in Maharashtra, offering a comprehensive range of services in pathology, radiology, and cardiology. The company focuses on delivering accurate diagnoses and precise reporting to enhance patient care. In addition to its diagnostic services, Suburban Diagnostics provides health check-ups, ensuring a holistic approach to health management for its clients. Through its commitment to quality and precision, the company aims to support healthcare providers in improving patient outcomes.

BGI

Venture Round in 2012
BGI is a biotechnology company specializing in genomics, providing genome sequencing and genetic testing services to research institutions and healthcare professionals. Operating through its subsidiary, Shenzhen Huada Gene Technology Co. Ltd., BGI offers a wide range of services including bioinformatics testing, agricultural genomics research, and proteomics research. The company collaborates with various organizations to enhance research efforts in the pharmaceutical and healthcare sectors. BGI also supplies products such as DNA extraction kits and other related tools, positioning itself as a key player in advancing genetic and genomic research.

Glocal Healthcare

Corporate Round in 2012
Glocal Healthcare is focused on improving healthcare delivery, particularly in rural areas of India, by utilizing a technology-enabled platform. The company operates a network of hospitals that offer a range of services, including outpatient and inpatient care, emergency services, and obstetric treatment, alongside digital dispensaries and telemedicine options. Glocal’s approach makes healthcare more affordable, accessible, and accountable, even in regions where traditional healthcare providers face challenges. It has developed two mobile applications, hellolyf and hellolyf Dr, which facilitate healthcare access for patients. With 250 telemedicine and IoT-based digital clinics, as well as ten hospitals, Glocal Healthcare aims to enhance the speed and effectiveness of treatment, ensuring better health outcomes for communities in need.

Moolchand Healthcare

Venture Round in 2012
Moolchand Healthcare is a prominent healthcare service provider based in Delhi, India, specializing in multi-specialty hospital operations. The organization features specialty hospitals staffed with internationally trained and globally recognized physicians, ensuring high-quality medical care. Moolchand Healthcare is committed to utilizing state-of-the-art technology and clinical innovations, providing patients with access to advanced treatment options for various life-threatening and acute physical ailments. The infrastructure of Moolchand Healthcare is designed to meet world-class standards, enhancing the overall patient experience and outcomes.

Hinacom Software and Technology

Series B in 2011
Hinacom Software and Technology, Ltd. is a healthcare IT company specializing in medical imaging and information management solutions. Based in Beijing, China, the company offers its miPlatform, an integrated medical imaging suite that encompasses various components such as Enterprise PACS/RIS, Regional PACS, TeleMed/TeleRad, web-based 3D processing, clinical image-based conferencing, and mobile imaging systems. The Enterprise PACS/RIS system is designed with a browser/server architecture to enhance workflow management, while the Regional PACS system facilitates patient-centered collaboration for medical imaging services across multiple hospitals in a region. The TeleMed/TeleRad system enables image transmission, viewing, and conferencing within web environments. Hinacom's solutions are utilized by hospitals and teleradiology projects in China, as well as by radiologists and clinicians in the United States, Europe, and Southeast Asia. Founded in 2008, the company has established itself as a key player in the medical imaging industry.

Moolchand Healthcare

Venture Round in 2011
Moolchand Healthcare is a prominent healthcare service provider based in Delhi, India, specializing in multi-specialty hospital operations. The organization features specialty hospitals staffed with internationally trained and globally recognized physicians, ensuring high-quality medical care. Moolchand Healthcare is committed to utilizing state-of-the-art technology and clinical innovations, providing patients with access to advanced treatment options for various life-threatening and acute physical ailments. The infrastructure of Moolchand Healthcare is designed to meet world-class standards, enhancing the overall patient experience and outcomes.

Glocal Healthcare

Seed Round in 2011
Glocal Healthcare is focused on improving healthcare delivery, particularly in rural areas of India, by utilizing a technology-enabled platform. The company operates a network of hospitals that offer a range of services, including outpatient and inpatient care, emergency services, and obstetric treatment, alongside digital dispensaries and telemedicine options. Glocal’s approach makes healthcare more affordable, accessible, and accountable, even in regions where traditional healthcare providers face challenges. It has developed two mobile applications, hellolyf and hellolyf Dr, which facilitate healthcare access for patients. With 250 telemedicine and IoT-based digital clinics, as well as ten hospitals, Glocal Healthcare aims to enhance the speed and effectiveness of treatment, ensuring better health outcomes for communities in need.

Attenti

Venture Round in 2009
Attenti, formerly known as Dmatek, is a global provider of remote monitoring technologies, primarily serving the criminal justice sector and senior housing markets. The company develops, manufactures, and supplies innovative presence and location verification solutions, including wireless monitoring systems that integrate wandering prevention, nurse call functions, and resident well-being monitoring. Attenti's product offerings feature solutions such as automatic alerts for residents approaching monitored areas, streamlined communication systems for staff, and tools for asset tracking and device management. Founded in 1990 and headquartered in Tel Aviv, Israel, Attenti has expanded its operations internationally, with a presence in the United States, Latin America, Europe, and the Pacific Rim. The company partners with public and private organizations, monitoring service providers, and government agencies across more than 25 countries.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.